Pixuvri pixantrone regulatory update

Cell Therapeutics submitted an MAA to the European Medicines Agency (EMA) for Pixuvri pixantrone as monotherapy to treat adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). The submission follows a positive opinion issued last month from EMA's Pediatric Committee (PDCO) agreeing to the company's pediatric investigation plan (PIP) for pixantrone to treat lymphoid malignancies and solid tumors in children ages 6 months to 18 years (see BioCentury, Oct. 25). ...